Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0R7HO
|
|||
| Former ID |
DAP000361
|
|||
| Drug Name |
Bumetanide
|
|||
| Synonyms |
Aquazone; Bumedyl; Bumetanida; Bumetanidum; Bumethanide; Bumex; Burine; Burinex; Butinat; Cambiex; Diurama; Drenural; Fontego; Fordiuran; Lixil; Lunetoron; Miccil; Segurex; Yurinex; AstraZeneca Brand of Bumetanide; Atlantis Brand of Bumetanide; Bumetanide AstraZeneca Brand; Bumetanide Atlantis Brand; Bumetanide Farmacusi Brand; Bumetanide Grossmann Brand; Bumetanide Leo Brand; Bumetanide Roche Brand; Bumetanide Senosiain Brand; Farmacusi Brand of Bumetanide; Grossmann Brand of Bumetanide; Leo Brand of Bumetanide; Roche Brand of Bumetanide; Senosiain Brand of Bumetanide; B 3023; PF 1593; PF1593; Bumetanida [INN-Spanish]; Bumetanidum [INN-Latin]; Bumex (TN); Bumex, Bumetanide; Lixil-Leo; PF-1593; Ro 10-6338; Bumetanide (JP15/USP); Ro-10-6338; Bumetanide (JP15/USP/INN); Bumetanide [USAN:BAN:INN:JAN]; 3-(Aminosulfonyl)-5-(butylamino)-4-phenoxybenzoic acid; 3-(Butylamino)-4-phenoxy-5-sulfamoylbenzoic acid; 3-(aminosulfonyl)-5-(butylamino)-4-(phenyloxy)benzoic acid; 3-butylamino-4-(phenoxy)-5-sulfamoylbenzoic acid
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Congestive heart failure [ICD-11: BD10; ICD-10: I50.0] | Approved | [1], [2] | |
| Therapeutic Class |
Diuretics
|
|||
| Company |
Hoffmann-La Roche pharmaceutical company
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C17H20N2O5S
|
|||
| Canonical SMILES |
CCCCNC1=C(C(=CC(=C1)C(=O)O)S(=O)(=O)N)OC2=CC=CC=C2
|
|||
| InChI |
1S/C17H20N2O5S/c1-2-3-9-19-14-10-12(17(20)21)11-15(25(18,22)23)16(14)24-13-7-5-4-6-8-13/h4-8,10-11,19H,2-3,9H2,1H3,(H,20,21)(H2,18,22,23)
|
|||
| InChIKey |
MAEIEVLCKWDQJH-UHFFFAOYSA-N
|
|||
| CAS Number |
CAS 28395-03-1
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID |
855675, 4652638, 7847313, 8149787, 8151648, 10321639, 11110843, 11110844, 11120301, 11120789, 11121277, 11121573, 11122053, 11335209, 11360448, 11362642, 11364211, 11365204, 11366773, 11367766, 11369335, 11370555, 11370556, 11372660, 11373367, 11373578, 11375928, 11377497, 11461420, 11466304, 11467424, 11484716, 11486107, 11488866, 11491296, 11491845, 11495131, 14852701, 17404725, 24278265, 26612248, 26680422, 26746951, 26746952, 26751481, 26758346, 29221635, 46508147, 47216571, 47440017
|
|||
| ChEBI ID |
CHEBI:3213
|
|||
| ADReCS Drug ID | BADD_D00307 | |||
| SuperDrug ATC ID |
C03CA02
|
|||
| SuperDrug CAS ID |
cas=028395031
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Solute carrier family 12 member 1 (SLC12A1) | Target Info | Blocker | [3], [4] |
| KEGG Pathway | Salivary secretion | |||
| Pancreatic secretion | ||||
| Vibrio cholerae infection | ||||
| Pathwhiz Pathway | Kidney Function | |||
| Reactome | Cation-coupled Chloride cotransporters | |||
| WikiPathways | miR-targeted genes in squamous cell - TarBase | |||
| miR-targeted genes in muscle cell - TarBase | ||||
| miR-targeted genes in lymphocytes - TarBase | ||||
| miR-targeted genes in epithelium - TarBase | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 4837). | |||
| REF 2 | FDA Approved Drug Products from FDA Official Website. 2009. Application Number: (ANDA) 074225. | |||
| REF 3 | Nerve Terminal GABAA Receptors Activate Ca2+/Calmodulin-dependent Signaling to Inhibit Voltage-gated Ca2+ Influx and Glutamate Release. J Biol Chem. 2009 Mar 27;284(13):8726-37. | |||
| REF 4 | Effect of L-ascorbate on chloride transport in freshly excised sinonasal epithelia. Am J Rhinol Allergy. 2009 May-Jun;23(3):294-9. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.